Table 1.

Clinical and Serological Data From MMP Patients With Associated Malignancies at the University of Bologna

No.	Sex/Age at Diagnosis of MMP (yr)	Sites Involved	Interval Between MMP Onset and Tumor Diagnosis	Associated Malignancy	BP Antigens BP180 and BP230	Anti-laminin-332	Treatment and Follow-up
1	F/66 (2014)	Oral/genital, ocular	1 yr before MMP onset	Breast cancer	Negative	Negative	MMP developed after 1 yr of surgery for breast cancer. Follow-up treatment with dapsone 200 mg/d and prednisone 7.5 mg/d without recurrence.
2	M/82 (2014)	Skin/oral/ocular	1 yr after MMP onset	Metastatic laryngeal SCC	Negative	Negative	During methylprednisolone treatment, the patient developed laryngeal SCC that became metastatic after 1 yr. The steroid was discontinued and treatment with dapsone 200 mg/d in addition to radiotherapy and chemotherapy was started. He died after 6 mos.
3	M/48 (2013)	Oral	3 yrs after MMP onset	Prostatic AC	Negative	ND	Oral MMP, involving exclusively the hard palate and the gums. Systemic steroids and dapsone with favorable results until complete remission. Prostatic AC after 3 yrs. Follow-up without MMP relapses.
4	F/83 (2016)	Ocular	1 yr after MMP onset	Hepatic cancer	Negative	Negative	Breast cancer at age 72, mastectomy, and liver cirrhosis for chronic hepatitis, with eye MMP, under treatment with methylprednisolone. Hepatocarcinoma developed recently during follow-up.

AC = adenocarcinoma; BP = bullous pemphigoid; ND = not done; SCC = squamous cell carcinoma.